Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25109301 | 1.00 | CNR1 (0.44) | CNR1CNR2EPHX2HPGDLMNA | |
| SCHEMBL25109478 | 1.00 | CNR1 (0.44) | CNR1CNR2EPHX2HPGDLMNA | |
| SCHEMBL22794305 | 1.00 | CNR1 (0.44) | CNR1CNR2EPHX2HPGDLMNA | |
| SCHEMBL25109749 | 0.94 | HPGD (0.46) | CNR1CNR2EPHX2HPGDLMNA | |
| SCHEMBL25109494 | 0.94 | HPGD (0.46) | CNR1CNR2EPHX2HPGDLMNA | |
| SCHEMBL24725453 | 0.90 | HPGD (0.44) | CNR1CNR2EPHX2HPGDLMNA | |
| SCHEMBL25468400 | 0.90 | EPHX2 (0.48) | CNR1CNR2EPHX2HPGDLMNA | |
| SCHEMBL25110465 | 0.90 | EPHX2 (0.48) | CNR1CNR2EPHX2HPGDLMNA | |
| SCHEMBL25110997 | 0.90 | EPHX2 (0.48) | CNR1CNR2EPHX2HPGDLMNA | |
| SCHEMBL25468398 | 0.90 | EPHX2 (0.48) | CNR1CNR2EPHX2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | CNR1 3006/4885CNR2 4133/4885EPHX2 3163/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | CNR1 2257/4885CNR2 3630/4885EPHX2 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.